Frequency's series A round brings in $32M

Regenerative medicine company Frequency Therapeutics Inc. (Woburn, Mass.) raised $32 million in a series A round led by CoBro Ventures. Also participating were Morningside Ventures, Emigrant Capital, Korean Investment Partnership, Alexandria Real Estate Equities and undisclosed U.S. and international investors.

CSO Chris Loose told BioCentury that Frequency expects to begin clinical testing by mid-2018 of its lead candidate to treat chronic noise-induced hearing loss. The company developed the candidate using its Progenitor Cell Activation (PCA) platform, which uses small molecules in combination to first trigger proliferation of dormant progenitor cells, then induce them to differentiate and replace damaged tissue (see BioCentury Innovations, Jan. 11). ...